IL153576A0 - Dna vaccines encoding hiv accessory proteins - Google Patents

Dna vaccines encoding hiv accessory proteins

Info

Publication number
IL153576A0
IL153576A0 IL15357601A IL15357601A IL153576A0 IL 153576 A0 IL153576 A0 IL 153576A0 IL 15357601 A IL15357601 A IL 15357601A IL 15357601 A IL15357601 A IL 15357601A IL 153576 A0 IL153576 A0 IL 153576A0
Authority
IL
Israel
Prior art keywords
dna vaccines
accessory proteins
encoding hiv
vaccines encoding
hiv accessory
Prior art date
Application number
IL15357601A
Other languages
English (en)
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of IL153576A0 publication Critical patent/IL153576A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL15357601A 2000-07-14 2001-07-12 Dna vaccines encoding hiv accessory proteins IL153576A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21819200P 2000-07-14 2000-07-14
PCT/US2001/041357 WO2002006303A2 (en) 2000-07-14 2001-07-12 Dna vaccines encoding hiv accessory proteins

Publications (1)

Publication Number Publication Date
IL153576A0 true IL153576A0 (en) 2003-07-06

Family

ID=22814104

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15357601A IL153576A0 (en) 2000-07-14 2001-07-12 Dna vaccines encoding hiv accessory proteins
IL153576A IL153576A (en) 2000-07-14 2002-12-22 DNA vaccines that target HIV helper proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153576A IL153576A (en) 2000-07-14 2002-12-22 DNA vaccines that target HIV helper proteins

Country Status (15)

Country Link
US (1) US7488484B2 (zh)
EP (1) EP1301637B1 (zh)
JP (1) JP2004525604A (zh)
KR (1) KR100815888B1 (zh)
CN (1) CN1312171C (zh)
AT (1) ATE398188T1 (zh)
AU (2) AU2001283493B2 (zh)
BR (1) BR0112486A (zh)
CA (1) CA2415187C (zh)
DE (1) DE60134408D1 (zh)
DK (1) DK1301637T3 (zh)
ES (1) ES2307640T3 (zh)
IL (2) IL153576A0 (zh)
PT (1) PT1301637E (zh)
WO (1) WO2002006303A2 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483640A1 (en) * 2002-05-16 2003-11-27 Bavarian Nordic A/S Fusion protein of hiv regulatory/accessory proteins
TW200613554A (en) * 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CA3184778A1 (en) 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
CN101897964B (zh) * 2009-04-27 2013-04-10 中国农业大学 一种预防自身免疫疾病的药物
KR20120093941A (ko) * 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
WO2015106003A1 (en) 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Ras pathways as markers of protection against hiv and methods to improve vaccine efficacy
WO2024144267A1 (ko) * 2022-12-27 2024-07-04 (주)한국바이오셀프 Hiv-1 mrna를 포함하는 백신 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS61170732A (ja) * 1985-01-25 1986-08-01 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
WO1990010693A1 (en) 1989-03-08 1990-09-20 Health Research, Inc. Recombinant poxvirus host selection system
JP3004049B2 (ja) 1989-03-31 2000-01-31 ワシントン ユニバーシティー 病原性のないｐｈｏＰ型微生物を含有するワクチン
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5482701A (en) * 1993-05-03 1996-01-09 Church & Dwight Co., Inc. Microporous alkali metal bicarbonate
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5861161A (en) * 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
JP2967094B2 (ja) * 1995-11-02 1999-10-25 工業技術院長 窒化アルミニウム焼結体、及び窒化アルミニウム粉末の製造方法
ATE512231T1 (de) 1998-02-27 2011-06-15 Univ Pennsylvania Impfstoffe, immuntherapeutika und verfahren zur anwendung derselben
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof

Also Published As

Publication number Publication date
CA2415187C (en) 2013-06-18
CN1636013A (zh) 2005-07-06
AU8349301A (en) 2002-01-30
CA2415187A1 (en) 2002-01-24
PT1301637E (pt) 2008-09-18
WO2002006303A2 (en) 2002-01-24
AU2001283493B2 (en) 2006-11-30
BR0112486A (pt) 2004-12-07
JP2004525604A (ja) 2004-08-26
DK1301637T3 (da) 2008-09-29
WO2002006303A3 (en) 2002-08-15
DE60134408D1 (de) 2008-07-24
EP1301637A4 (en) 2005-06-01
CN1312171C (zh) 2007-04-25
US7488484B2 (en) 2009-02-10
EP1301637B1 (en) 2008-06-11
US20040106100A1 (en) 2004-06-03
KR100815888B1 (ko) 2008-03-21
EP1301637A2 (en) 2003-04-16
ATE398188T1 (de) 2008-07-15
ES2307640T3 (es) 2008-12-01
KR20030016374A (ko) 2003-02-26
IL153576A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
EP1381280A4 (en) VIRAL VECTORS AND USE THEREOF IN THERAPEUTIC METHODS
WO2002028867A3 (en) Ethers of 7-desmethylrapamycin for use in immunosuppression
WO2002028866A3 (en) Hydroxyesters of 7-desmethylrapamycin
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
BR0113975A (pt) ésteres de rapamicina solúveis em água
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
DE69929232D1 (de) Virusähnliche partikel zur induktion von autoantikörpern
ATE319825T1 (de) Verfahren und zusammensetzungen zur immunomodulation
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
IL145795A0 (en) Mutant human cd80 and compositions for and methods of making and using the same
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2003103571A3 (en) VACCINES AGAINST FLAVIVIRUSES
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
IL153359A0 (en) Peptides, compositions and methods for the treatment of burkholderia cepacia
HK1054192A1 (en) Kahalalide formulation
DE69911401D1 (en) Immunoregulator
AU8349301A (en) Dna vaccines encoding hiv accessory proteins
WO2003092632A3 (en) Cyclic peptide anti-cancer agents and methods
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
WO2002077233A8 (en) 38650, 28472, 5495, 65507, 81588 and 14354 METHODS AND COMPOSITIONS OF HUMAN PROTEINS AND USES THEREOF
CY1108543T1 (el) Εμβολια dna που κωδικοποιουν βοηθητικες πρωτεϊνες του hiv
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins